Latest CARTITUDE-4 Data Highlight the Benefits of Cilta-Cel in Multiple Myeloma

by | Sep 27, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.
Read More

Submit a Comment